Thermo Fisher Scientific acquires PeproTech for US $1.85 bn
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Partnering to build biosynthesis processes and a pharmaceutical production platform
The QuickVue antigen tests are able to detect the live Omicron variant with similar performance as with other variants
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services, is part of an effort to ensure secure local supply and production capacity for critical products for pandemic preparedness
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
Subscribe To Our Newsletter & Stay Updated